Trial Profile
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Capecitabine; Lapatinib; Trastuzumab
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Breast02; DS8201-A-U301
- Sponsors Daiichi Sankyo Inc
- 12 Apr 2024 The trial has been completed in Germany, according to European Clinical Trials Database record.
- 13 Mar 2024 Planned End Date changed from 1 Sep 2024 to 1 May 2025.
- 08 Mar 2024 The trial has been completed in Czechia, according to European Clinical Trials Database record.